Evidence map›Paper›PMID 23114698›Full record

ArticleClinical and vaccine immunology : CVI2013

Rational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination.

Vincent J Venditto, Douglas S Watson, Michael Motion, David Montefiori, Francis C Szoka

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Vincent J VendittoDepartments of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California, San Francisco, CA, USA.
Douglas S Watson
Michael Motion
David Montefiori
Francis C Szoka
University of California, San Francisco · USDuke Medical Center · USUniversity of California, Berkeley · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Targeted Drug Delivery to Surface Receptors.R01GM061851 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SZOKA, FRANCIS C. · 2001 to 2015
$3.5M
HIV neutralizing antibodies induced by chemically modified MPR epitopesR21AI093135 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SZOKA, FRANCIS C. · 2011 to 2012
$425k
Do peptide mimetics of gp41 improve antibody-epitope interactions?F32AI095062 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VENDITTO, VINCENT JOSEPH · 2012 to 2014
$163k
NIAID NIH HHS F32 AI095062NIAID NIH HHS P30 AI027763NIAID NIH HHS P30-AI027763NIAID NIH HHS R21 AI093135NIGMS NIH HHS R01 GM061851
6 · The paper itself

Abstract

The inability to generate broadly neutralizing antibody (bnAb) responses to the membrane proximal external region (MPER) of HIV-1 gp41 using current vaccine strategies has hampered efforts to prevent the spread of HIV. To address this challenge, we investigated a novel hypothesis to help improve the anti-MPER antibody response. Guided by structural insights and the unique lipid reactivity of anti-MPER bnAbs, we considered whether amino acid side chain modifications that emulate hydrophilic phospholipid head groups could contribute to the generation of 2F5-like or 4E10-like neutralizing anti-MPER antibodies. To test this hypothesis, we generated a series of chemically modified MPER immunogens through derivatization of amino acid side chains with phosphate or nitrate groups. We evaluated the binding affinity of the chemically modified peptides to their cognate monoclonal antibodies, 2F5 and 4E10, using surface plasmon resonance. The modifications had little effect on binding to the antibodies and did not influence epitope secondary structure when presented in liposomes. We selected five of the chemically modified sequences to immunize rabbits and found that an immunogen containing both the 2F5 and 4E10 epitopes and a phosphorylated threonine at T676 elicited the highest anti-peptide IgG titers, although the high antipeptide titers did not confer higher neutralizing activity. These data indicate that side chain modifications adjacent to known neutralizing antibody epitopes are capable of eliciting antibody responses to the MPER but that these chemically modified gp41 epitopes do not induce neutralizing antibodies.

Indexed as

AIDS VaccinesAnimalsAntibodies, NeutralizingDrug DesignHIV AntibodiesHIV Envelope Protein gp41Immunoglobulin GLipopeptidesRabbitsVaccinationAIDS VaccinesAntibodies, Neutralizinggp41 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp41Immunoglobulin GLipopeptides

Identifiers

PMID23114698
PMCPMC3535774
OpenAlexW2130972492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.